Revenue distribution by industry:

• Pharmaceutical products: 45%
• Cosmetics and personal care products: 30%
• Food and beverages: 15%
• Other products: 10%

TOP 3 markets and their percentage shares:

• Japan: 70%
• China: 15%
• South Korea: 10%

COSMOS Pharmaceutical Corporation generates the majority of its revenue from the sale of pharmaceutical products, followed by cosmetics and personal care products. The main market is Japan, where the company has its strongest presence. China and South Korea are also significant markets, together accounting for a substantial portion of international revenue.

This distribution demonstrates COSMOS's strong local market position in Japan and strategic expansion into Asian markets.

Production Sites: Japan

COSMOS Pharmaceutical Corporation produces the majority of its products in Japan. The company is known for its strong presence in the Japanese market and operates several production facilities there. This local production enables COSMOS to efficiently meet the high demand for pharmaceutical products and drugstore items while maintaining the high quality standards that are prevalent in Japan.

Additionally, the company may also collaborate with external manufacturers to complement certain products, but the main focus remains on domestic production.

Revenue Growth: 8.5% (estimated 2024)
Profit Growth: 10.2% (estimated 2024)

COSMOS Pharmaceutical Corporation pursues a multi-pronged growth strategy focusing on expanding its branch network, digitalization, and diversifying its product offering.

The company plans to enhance its presence in urban and rural areas by opening new branches. This is intended not only to increase market penetration but also to improve customer proximity.

Simultaneously, COSMOS is investing in digital platforms to strengthen online sales and provide customers with a seamless shopping experience. This strategy aims to capitalize on the growing trend of e-commerce in the pharmaceutical sector.

Additionally, the company is diversifying its product portfolio by introducing new health and wellness products to meet changing consumer needs. These measures are intended to make the company more resilient to market fluctuations and ensure long-term growth.

Main Imported Raw Materials: Pharmaceutical active ingredients, packaging materials

Main Import Countries: China, India, Germany

COSMOS Pharmaceutical Corporation mainly imports pharmaceutical active ingredients needed for the production of their products. These active ingredients are mainly sourced from China and India, as these countries are leading in the production of generics and pharmaceutical raw materials.

In addition, packaging materials such as special plastics and glass are imported from Germany, which is known for its high-quality packaging solutions. These materials are crucial for ensuring product quality and safety.

Market share in Japan: 10% (estimated 2025)
Revenue growth: 8% (2024)
Profit margin: 5.5% (2024)

COSMOS Pharmaceutical Corporation has a significant competitive advantage in the Japanese market, mainly due to its strong presence and dense network of branches. With an estimated market share of 10% in 2025, the company is among the industry's leading players.

The 8% revenue growth in 2024 indicates that COSMOS is able to further expand its market position, despite intense competition. The 5.5% profit margin suggests that the company operates efficiently and manages its costs well.

Another competitive advantage lies in high customer loyalty and a wide range of products, including both medications and everyday consumer goods. This allows COSMOS to benefit from various revenue sources and protect itself against economic fluctuations.

Institutional Investor Share: 45% (2025, estimated)
Insider Purchases: No significant purchases (last 12 months)
Insider Sales: 2% of outstanding shares (last 12 months)

The institutional investor share in COSMOS Pharmaceutical Corporation is estimated to be around 45%. This indicates a strong interest from institutional investors in the stock, suggesting confidence in the company's strategy and performance.

There have been no significant insider purchases in the last 12 months, which could indicate that management considers the current valuation of the stock to be fair. However, about 2% of outstanding shares were sold by insiders, which is typically seen as a sign that insiders are realizing profits or looking to diversify their portfolios.

Market share of COSMOS Pharmaceutical Corporation: 12% (2025, estimated)

Top competitors and their market shares:

1. Matsumotokiyoshi Holdings Co., Ltd.: 18%
2. Welcia Holdings Co., Ltd.: 15%
3. Sugi Holdings Co., Ltd.: 10%
4. Tsuruha Holdings Inc.: 9%
5. Kokumin Co., Ltd.: 8%
6. Create SD Holdings Co., Ltd.: 7%
7. Sun Drug Co., Ltd.: 6%
8. Ain Holdings Inc.: 5%

COSMOS Pharmaceutical Corporation holds a significant market share of 12%, making it one of the leading companies in the Japanese pharmaceutical retail industry. Their moat mainly consists of a strong branch network, an efficient supply chain, and high customer loyalty through competitive prices and a wide range of products.

Compared to competitors, Matsumotokiyoshi Holdings has the largest market share and a strong moat due to their brand recognition and innovation in customer retention technologies. Welcia Holdings benefits from strategic partnerships and solid expansion in urban areas.

While COSMOS has a solid moat, competitors could have an advantage through greater geographical reach and technological innovations. Competition remains intense, and success will heavily depend on the ability to adapt to market changes and effectively meet customer needs.

Revenue Growth: 8.5% (2024) Profit Growth: 7.2% (2024) Market Share in Retail: 12% (2024)

COSMOS Pharmaceutical Corporation achieved solid revenue growth of 8.5% in 2024, attributed to successful expansion and a strong market position in the retail sector. The 7.2% profit growth indicates the company's ability to increase profitability despite a competitive market.

The company has increased its market share in retail to 12%, highlighting its competitiveness and ability to gain market share from competitors. These factors point to a positive business development.

COSMOS Pharmaceutical is also investing in new technologies and store expansions to enhance its operational efficiency and improve the customer experience. These strategic initiatives could further support future growth.

Overall, COSMOS Pharmaceutical Corporation demonstrates strong fundamental metrics and a clear growth strategy, making it a potentially attractive investment, especially for investors focusing on long-term growth.

Dividend Yield: 1.8% (2025)
Dividend History: Consistent payout over the last 5 years

COSMOS Pharmaceutical Corporation has regularly distributed dividends in recent years, indicating a reliable dividend policy. The current dividend yield is 1.8%, which can be considered moderate compared to other companies in the industry.

The consistent payout over the last five years suggests that the company has stable financial foundations. This stability is supported by a solid market position and continuous revenue growth. Analysts expect that COSMOS Pharmaceutical will continue to be able to reliably distribute dividends in the future, provided that no significant market changes occur.